|Bid||0.2000 x N/A|
|Ask||0.2300 x N/A|
|Day's Range||0.2000 - 0.2000|
|52 Week Range||0.1500 - 0.3500|
|Beta (3Y Monthly)||-0.29|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
TORONTO, May 7, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTC:FSDDF - News) (FRA: 0K9) ("FSD Pharma" or "FSD") and Solarvest BioEnergy Inc. (TSX-V:SVS.V - News) ("Solarvest"), a technology company that developed an algal-based flexible production platform capable of producing health products, announced today that they signed a definitive collaborative research and development agreement. Under the agreement, Solarvest will conduct research using its algal expression technology to develop pharmaceutical-grade cannabinoids. FSD Pharma and Solarvest have made investments into one another and FSD has the option to enter into an exclusive license arrangement over a subset of the project and receive royalty rights over all of the products that result from the project.
TORONTO, Feb. 5, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) ("FSD Pharma") and Solarvest BioEnergy Inc. (TSX-V:SVS.V - News) ("Solarvest") (collectively, the "Parties"), a technology company which has developed an algal-based flexible production platform capable of producing health products, are pleased to announce that they have signed a non-binding letter of intent ("LOI"). The parties intend to enter into a definitive agreement (the "Collaborative Research Agreement"), under which Solarvest would conduct research using its algal expression technology to develop pharma-grade cannabinoids (the "Project Cannabinoids"), the Parties would make mutual investments into one another, and Solarvest would grant FSD Pharma an exclusive license over a subset of the Project Cannabinoids and certain royalty rights over all of the other Project Cannabinoids.